ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,995.54
      0.38%
      US Tech 100
      20,562.00
      0.10%
      Dow Jones
      43,988.99
      0.59%
      Brent Oil
      73.885
      0.00%
      Bitcoin
      80,678.72
      5.07%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Rigel Pharmaceuticals Inc (RIGL) Quote

      Rigel Pharmaceuticals Inc

      Rigel Pharmaceuticals Inc (RIGL)

      NASDAQ
      22.07
      6.63
      (42.94%)
      Closed November 10 4:00PM
      Delayed by 15 minutes
      21.60
      -0.47
      (-2.13%)
      After Hours: 7:33PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      21.60
      Bid
      20.90
      Ask
      21.75
      Volume
      1,306,957
      16.65 Day's Range 22.85
      7.4843 52 Week Range 21.93
      Market Cap
      380.052M
      Previous Close
      15.44
      Open
      16.65
      Last Trade
      20
      @
      21.75
      Last Trade Time
      Financial Volume
      $ 26,042,428
      VWAP
      19.926
      Average Volume (3m)
      138,507
      Shares Outstanding
      17,594,977
      Dividend Yield
      -
      PE Ratio
      -15.38
      Earnings Per Share (EPS)
      -1.43
      Revenue
      116.88M
      Net Profit
      -25.09M

      About Rigel Pharmaceuticals Inc

      Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For mor... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit https://www.rigel.com/. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.rigel.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RIGL. The last closing price for Rigel Pharmaceuticals was $15.44. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of $ 7.4843 to $ 21.93.

      Rigel Pharmaceuticals currently has 17,594,977 shares outstanding. The market capitalization of Rigel Pharmaceuticals is $271.67 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -15.38.

      Ask ADVFN Intelligence (AI)

      RIGL Latest News

      More News

      Form 8-K - Current report

      November 07 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 07 2024
      Edgar (US Regulatory)

      Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

      Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 7, 2024 Third quarter total revenue of $55.3 million, which includes...

      November 07 2024
      PR Newswire (US)

      Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

      Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 5, 2024 -    Initial data from the...

      November 05 2024
      PR Newswire (US)

      Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

      Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 SOUTH SAN FRANCISCO, Calif...

      October 31 2024
      PR Newswire (US)

      Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

      Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib) PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024...

      October 24 2024
      PR Newswire (US)

      Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

      ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel...

      October 16 2024
      GlobeNewswire Inc.

      Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 4, 2024 SOUTH SAN FRANCISCO, Calif., Oct. 4, 2024 /PRNewswire/ -- Rigel...

      October 04 2024
      PR Newswire (US)

      Form 8-K - Current report

      September 19 2024
      Edgar (US Regulatory)

      Rigel to Present at the 2024 Cantor Global Healthcare Conference

      Rigel to Present at the 2024 Cantor Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 12, 2024 SOUTH SAN FRANCISCO, Calif., Sept. 12, 2024 /PRNewswire/ -- Rigel...

      September 12 2024
      PR Newswire (US)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      17.8557.090909090913.7521.9313.636812270114.86394328CS
      46.3741.825344714415.2321.9313.570510342614.77371694CS
      129.1873.913043478312.4221.9311.95513850714.98609236CS
      2610.594.594594594611.121.937.48435632249.88280712CS
      5212.6140921.937.484391099611.6647359CS
      156-10.2-32.075471698131.835.156.4222803314.19639711CS
      2600.83.8461538461520.8556.4248553722.84580633CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      INODInnodata Inc
      $ 42.75
      (75.64%)
      		9.61M
      SEZLSezzle Inc
      $ 428.58
      (71.11%)
      		632.22k
      SONDSonder Holdings Inc
      $ 4.36
      (60.89%)
      		1.42M
      INDIindie Semiconductor Inc
      $ 5.50
      (60.35%)
      		36.22M
      AZIAutozi Internet Technology Global Ltd
      $ 2.54
      (55.83%)
      		13.41M
      PRPHProPhase Labs Inc
      $ 0.78
      (-45.45%)
      		2.65M
      ELWSEarlyworks Co Ltd
      $ 3.69
      (-45.33%)
      		854.2k
      ALVRAlloVir Inc
      $ 0.6103
      (-37.82%)
      		2.05M
      CHSNChanson International Holding
      $ 5.66
      (-37.60%)
      		529.66k
      RVNCRevance Therapeutics Inc
      $ 3.705
      (-35.90%)
      		12.98M
      ELABElevai Labs Inc
      $ 0.0188
      (5.03%)
      		434.16M
      TIVCTivic Health Systems Inc
      $ 0.4003
      (53.67%)
      		291.1M
      TSLATesla Inc
      $ 321.22
      (8.19%)
      		203.89M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 19.06
      (16.29%)
      		187.02M
      NVDANVIDIA Corporation
      $ 147.63
      (-0.84%)
      		175.09M

      RIGL Discussion

      View Posts
      dcaf7 dcaf7 7 months ago
      Titles of olutasidenib presentations at ASCO:
      1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
      2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
      3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
      👍️0
      Monksdream Monksdream 7 months ago
      RIGL under $2
      👍️0
      Monksdream Monksdream 7 months ago
      RIGL under $2
      👍️0
      dcaf7 dcaf7 7 months ago
      Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
      https://pubmed.ncbi.nlm.nih.gov/38538632/
      👍️0
      dcaf7 dcaf7 8 months ago
      Good read on Olutasidenib
      https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
      Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
      👍️0
      dcaf7 dcaf7 9 months ago
      Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
      FEBRUARY 22, 2024 7:50AM EST
      GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
      Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
      GAVRETO generated ~$28M in U.S. net product sales in 2023
      👍️0
      bme bme 1 year ago
      Rigl should be VTGN (Today) one day.
      👍️0
      bme bme 1 year ago
      Yeah. Should be good Q.
      👍️0
      TucsonPhil TucsonPhil 1 year ago
      Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
      👍️0
      bme bme 1 year ago
      Better be good.
      👍️0
      bme bme 1 year ago
      Ugly.
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      base
      👍️0
      bme bme 1 year ago
      What a shoot! Amazing.
      👍️0
      bme bme 1 year ago
      The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
      1. What else should we expect as for the rev?
      2. Result of phase 3 of Fostamatinib3 COVID 19?
      3. Status of Fostamatinib-ACTIV4 COVID 19?
      4. Partnered Programs?
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice fins
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      gem
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      gem
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      easy
      👍️0
      bme bme 1 year ago
      Nice spike AH today.
      👍️0
      bme bme 1 year ago
      Higher low higher low.... next leg is North.
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
      👍️0
      bme bme 1 year ago
      acting wild atm, but still healthy.
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      bme bme 1 year ago
      Nice & Healthy.
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      quite the dip
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      ready
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      ready
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      red to green
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      red to green
      👍️0
      bme bme 1 year ago
      Wonderful!
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      beauty
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      bme bme 2 years ago
      Expect Q4 filing this week?
      👍️0
      bme bme 2 years ago
      Be seeing that. Lot of 1.95 transactions so far
      👍️0
      TucsonPhil TucsonPhil 2 years ago
      Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
      👍️0
      bme bme 2 years ago
      SP should be a lot higher since the Q4 revenue is more than double from last year...
      👍️0
      Welldoctor Welldoctor 2 years ago
      Apparently insider buying reported on ST. Take it for what it’s worth.
      👍️0
      Welldoctor Welldoctor 2 years ago
      RIGL news out
      👍️0
      bme bme 2 years ago
      Looks like it will poke thru & bye bye 1 today.
      👍️0
      doesitreallymatter doesitreallymatter 2 years ago
      Just like ABQQ. Right?
      👍️0
      subslover subslover 2 years ago
      You are 1/2 way there!!!!
      👍️0
      KngmAz KngmAz 2 years ago
      Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
      👍️0
      KngmAz KngmAz 2 years ago
      This is a $10.00 per share stock in the very near future - EASILY!!
      👍️0
      Alaska40 Alaska40 2 years ago
      I just bought in. Seems like a good run could come in the near future.
      👍️0
      subslover subslover 2 years ago
      Consolidating nicely on Continuation from last week!
      👍️0
      bcapps66 bcapps66 2 years ago
      LOL!
      👍️0
      THEMASTERS_SON THEMASTERS_SON 2 years ago
      GIVE ME MY $2DOLLAS…YA BUM
      👍️0

      Your Recent History

      NASDAQ
      RIGL
      Rigel Pharmaceuticals
      Delayed Upgrade Clock